

28. (new) The method of claim 27, wherein an exon encoding a biotin binding motif of ACC2 is replaced with an hypoxanthine phosphoribosyltransferase expression cassette.

Please cancel claims 1-14 and 16-23.

### REMARKS

#### Status of the claims

Claims 1-23 are pending and subject to restriction. Claims 1-14 and 16-23 are withdrawn from consideration and canceled. Claim 15 is amended herein. New claims 24-28 are added..

Attached hereto is a marked-up version of the changes made to the claims by the current amendments. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE". No new matter has been added. Consideration of the pending claims is respectfully requested.

#### Amendments to the claims


Claim 15 is amended to incorporate the limitations of claims 12-14 from which claim 15 depended. New claims 24-28 are added to

depend from amended claim 15 and to incorporate the limitations of claims 7-14 from which original claim 12 depended.

This is intended to be a complete response to the Restriction Requirement mailed December 12, 2002. If any issues remain outstanding, the Examiner is respectfully requested to telephone the undersigned attorney of record for immediate resolution. Applicants enclose herewith a Petition for a One Month Extension of Time. Please debit the \$55 extension fee under 37 C.F.R. 1.17(a) or any additional fees from Deposit Acct. No. 07-1185 on which the undersigned is allowed to draw.

Respectfully submitted,

Date: April 11, 2003  
ADLER & ASSOCIATES  
8011 Candle Lane  
Houston, Texas 77071  
(713) 270-5391  
badler1@houston.rr.com

  
Benjamin Aaron Adler, Ph.D., J.D.  
Counsel for Applicant  
Registration No. 35,423

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Please amend claim 15 as follows:

15. (amended) A method of screening for an inhibitor of acetyl-CoA carboxylase 2 isoform activity, comprising the steps of:

administering a potential inhibitors to one or more wild type mouse ~~mice~~; and,

screening ~~for mice~~ said one or more mouse for a which  
~~exhibit the~~ phenotype exhibited by a transgenic mouse of claim 14, said  
phenotype comprising:

a metabolic reduction in malonyl-CoA production in skeletal  
muscle and heart;

unrestricted fat oxidation and reduced fat accumulation in  
the liver and fat storage cells; and

consuming more calories than said one or more wild-type  
mouse.

Please cancel claims 1-14 and 16-23.